Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 1
1997 1
1998 2
1999 1
2000 8
2001 15
2002 51
2003 83
2004 111
2005 126
2006 128
2007 145
2008 253
2009 179
2010 258
2011 215
2012 213
2013 192
2014 232
2015 311
2016 312
2017 304
2018 290
2019 302
2020 334
2021 326
2022 345
2023 331
2024 342
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,844 results

Results by year

Filters applied: . Clear all
Page 1
Rosuvastatin/Ezetimibe: A Review in Hypercholesterolemia.
Lamb YN. Lamb YN. Am J Cardiovasc Drugs. 2020 Aug;20(4):381-392. doi: 10.1007/s40256-020-00421-1. Am J Cardiovasc Drugs. 2020. PMID: 32648167 Review.
Rosuvastatin/ezetimibe combines two lipid-lowering agents: rosuvastatin, an HMG-CoA reductase inhibitor (i.e. statin) with particularly strong inhibitory effects on hepatic cholesterol synthesis, and ezetimibe, which inhibits the intestinal absorption of cholesterol …
Rosuvastatin/ezetimibe combines two lipid-lowering agents: rosuvastatin, an HMG-CoA reductase inhibitor (i.e. statin) with particular …
Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights.
Chilbert MR, VanDuyn D, Salah S, Clark CM, Ma Q. Chilbert MR, et al. Drug Des Devel Ther. 2022 Jul 7;16:2177-2186. doi: 10.2147/DDDT.S332352. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 35832642 Free PMC article. Review.
The recent approval of a combination tablet of high-intensity rosuvastatin and ezetimibe has introduced a potentially more beneficial option for cholesterol management in addition to the only available combination of moderate intensity simvastatin and ezetimibe. We …
The recent approval of a combination tablet of high-intensity rosuvastatin and ezetimibe has introduced a potentially more beneficial …
PCSK9 inhibitor, ezetimibe, and bempedoic acid: Evidence-based therapies for statin-intolerant patients.
Gunta SP, O'Keefe JH, O'Keefe EL, Lavie CJ. Gunta SP, et al. Prog Cardiovasc Dis. 2023 Jul-Aug;79:12-18. doi: 10.1016/j.pcad.2023.02.007. Epub 2023 Mar 5. Prog Cardiovasc Dis. 2023. PMID: 36871887 Review.
Statins still dominate this landscape, but other agents, often used in combination, potently reduce LDL-C levels, regress atherosclerosis and lower risk of major adverse cardiovascular events (MACE). Ezetimibe lowers LDL-C by reducing intestinal absorption of cholesterol. …
Statins still dominate this landscape, but other agents, often used in combination, potently reduce LDL-C levels, regress atherosclerosis an …
Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study).
Cho Y, Rhee H, Kim YE, Lee M, Lee BW, Kang ES, Cha BS, Choi JY, Lee YH. Cho Y, et al. BMC Med. 2022 Mar 21;20(1):93. doi: 10.1186/s12916-022-02288-2. BMC Med. 2022. PMID: 35307033 Free PMC article. Clinical Trial.
BACKGROUND: The effect of ezetimibe, Niemann-Pick C1-like 1 inhibitor, on liver fat is not clearly elucidated. Our primary objective was to evaluate the efficacy of ezetimibe plus rosuvastatin versus rosuvastatin monotherapy to reduce liver fat using magnetic resona …
BACKGROUND: The effect of ezetimibe, Niemann-Pick C1-like 1 inhibitor, on liver fat is not clearly elucidated. Our primary objective …
Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial.
Ouchi Y, Sasaki J, Arai H, Yokote K, Harada K, Katayama Y, Urabe T, Uchida Y, Hayashi M, Yokota N, Nishida H, Otonari T, Arai T, Sakuma I, Sakabe K, Yamamoto M, Kobayashi T, Oikawa S, Yamashita S, Rakugi H, Imai T, Tanaka S, Ohashi Y, Kuwabara M, Ito H. Ouchi Y, et al. Circulation. 2019 Sep 17;140(12):992-1003. doi: 10.1161/CIRCULATIONAHA.118.039415. Epub 2019 Aug 22. Circulation. 2019. PMID: 31434507 Clinical Trial.
This trial tested whether LDL-C-lowering therapy with ezetimibe is useful for the primary prevention of cardiovascular events in older patients. ...Ezetimibe reduced the incidence of the primary outcome (hazard ratio [HR], 0.66; 95% CI, 0.50-0.86; P=0.002). ...
This trial tested whether LDL-C-lowering therapy with ezetimibe is useful for the primary prevention of cardiovascular events in olde …
Ezetimibe and Insulin Resistance.
Popovic DS, Papachristou S, Stokic E, Papanas N. Popovic DS, et al. Curr Vasc Pharmacol. 2022;20(4):315-317. doi: 10.2174/1570161120666220301140528. Curr Vasc Pharmacol. 2022. PMID: 35232351 No abstract available.
Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia.
Lee J, Lee SH. Lee J, et al. Korean J Intern Med. 2023 Nov;38(6):797-809. doi: 10.3904/kjim.2023.243. Epub 2023 Oct 20. Korean J Intern Med. 2023. PMID: 37866817 Free PMC article. Review.
This review provides a comprehensive analysis of the clinical implications of ezetimibe for managing dyslipidemia; it also evaluates the available evidence that supports the role of ezetimibe as an adjunct non-statin therapy for long-term use. ...Nonetheless, an und …
This review provides a comprehensive analysis of the clinical implications of ezetimibe for managing dyslipidemia; it also evaluates …
The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function.
Di Costanzo A, Indolfi C, Sorrentino S, Esposito G, Spaccarotella CAM. Di Costanzo A, et al. Int J Mol Sci. 2023 Jul 21;24(14):11739. doi: 10.3390/ijms241411739. Int J Mol Sci. 2023. PMID: 37511498 Free PMC article. Review.
Indeed, growing evidence supports the view that statins, ezetimibe, PCSK9 inhibitors, inclisiran, and icosapent ethyl also act as antithrombotics. ...
Indeed, growing evidence supports the view that statins, ezetimibe, PCSK9 inhibitors, inclisiran, and icosapent ethyl also act as ant …
Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis.
Lee C, Kwak SH, Han J, Shin JH, Yoo B, Lee YS, Park JS, Lim BJ, Lee JG, Kim YS, Kim SY, Bae SH. Lee C, et al. Eur Respir J. 2024 May 16;63(5):2300580. doi: 10.1183/13993003.00580-2023. Print 2024 May. Eur Respir J. 2024. PMID: 38359963 Free PMC article.
This study aimed to determine whether ezetimibe has therapeutic potential against idiopathic pulmonary fibrosis. METHODS: Primary lung fibroblasts isolated from both humans and mice were employed for mechanistic in vitro experiments. mRNA sequencing of human lung fibroblas …
This study aimed to determine whether ezetimibe has therapeutic potential against idiopathic pulmonary fibrosis. METHODS: Primary lun …
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial.
Ballantyne CM, Ditmarsch M, Kastelein JJ, Nelson AJ, Kling D, Hsieh A, Curcio DL, Maki KC, Davidson MH, Nicholls SJ. Ballantyne CM, et al. J Clin Lipidol. 2023 Jul-Aug;17(4):491-503. doi: 10.1016/j.jacl.2023.05.098. Epub 2023 Jun 3. J Clin Lipidol. 2023. PMID: 37277261 Free article. Clinical Trial.
OBJECTIVE: To evaluate the safety and lipid-altering efficacy of obicetrapib plus ezetimibe combination therapy as an adjunct to high-intensity statin therapy. METHODS: This double-blind, randomized, phase 2 trial administered 10 mg obicetrapib plus 10 mg ezetimibe …
OBJECTIVE: To evaluate the safety and lipid-altering efficacy of obicetrapib plus ezetimibe combination therapy as an adjunct to high …
4,844 results